Advances in clinical fibrinolysis

Area of Science:

• Biochemistry
• Hematology
• Physiology

Background:

• The balance between tissue-type plasminogen activator (t-PA) and its inhibitor dictates blood fibrinolytic activity.
• Acute-phase patterns of plasminogen activator inhibitor may influence thrombosis in acute conditions.

Purpose of the Study:

• To explore the regulatory mechanisms of the fibrinolytic system.
• To discuss the role of newly discovered modulators and therapeutic interventions in fibrinolysis.

Main Methods:

• Review of recent discoveries in fibrinolytic system research.
• Analysis of the role of fibrin as a cofactor in clot dissolution.
• Discussion of clinical trial results for fibrinolytic activators and inhibitors.

Main Results:

• Identification of a fast-acting plasminogen activator inhibitor with acute-phase properties.
• Discovery of new fibrinolytic system modulators: histidine-rich glycoprotein, tetranectin, and thrombospondin.
• Elucidation of fibrin's cofactor role in its own dissolution.

Conclusions:

• Therapeutic inhibition of fibrinolysis requires careful monitoring.
• Prophylactic stimulation of fibrinolysis has limited proven value.
• Understanding fibrinolytic system physiology is crucial for evaluating thrombolytic agents.